Matribhumi Samachar English
Toronto, Ontario–(Newsfile Corp. – September 3, 2026) – ALZAI Health Corp. (TSXV: ALZI) (FSE: H2F) (“ALZAI” or the “Company”), a healthcare technology company developing artificial intelligence-driven disease risk identification solutions, is pleased to announce that its common shares are now posted for trading on the Frankfurt Stock Exchange (“FSE”) under the symbol H2F.
The Frankfurt Stock Exchange is one of Europe’s leading securities trading venues, providing access to a broad base of institutional and retail investors.
About ALZAI Health Corp.
ALZAI Health Corp. is a healthcare technology company developing non-invasive, artificial intelligence-driven disease risk identification solutions using routine healthcare data. The Company’s proprietary platform is designed to identify individuals at elevated risk for disease before clinical diagnosis, enabling earlier intervention opportunities and supporting improved patient outcomes. ALZAI’s technology has been validated on large-scale healthcare datasets and is designed for integration into existing healthcare infrastructure, including electronic medical record systems, cloud-based environments, and enterprise healthcare platforms.
For more information and media inquiries, contact:
Hayim Raclaw
Chairman and Chief Executive Officer
Alzai Health Corp.
Email: [email protected]
Telephone: 416-862-4351
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information in this news release includes statements regarding the anticipated benefits of the Company’s shared being posted for trading on the Frankfurt Stock Exchange, including the potential to broaden the Company’s international capital markets presence, increase its visibility and awareness among European and international investors, and provide greater accessibility to the Company’s common shares, as well as statements regarding the advancement of the Company’s technology and commercial strategy.
Forward-looking information is based on management’s current expectations and assumptions and is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information. There can be no assurance that the Frankfurt listing will result in increased investor awareness, trading activity, liquidity or other anticipated benefits.
Readers are cautioned not to place undue reliance on forward-looking information. The forward-looking information contained in this news release is made as of the date hereof, and the Company undertakes no obligation to update or revise such information except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/312764
